NKCC2

近日，健康元药业集团股份有限公司 （以下简称 “ 健康元 ” ） 与成都金瑞基业生物科技有限公司 （以下简称 “ 金瑞 ” ） 签署了《战略合作备忘录》，就金瑞已取得的部分项目成果及双方关注的创新药研发领域开展战略合作。双方将 发挥各自优势，共同开展创新药物研发 ，在 优势产品适应症授权开发 、 合作项目产品的未来市场销售合作 以及 资本投资合作 等方面开展深入合作。同日，双方也就金瑞 J RF106 项目签订《技术合作研发协议》。 JRF106吸入溶液为金瑞自主研发的1类新药，临床拟定适应症为肺水肿。JRF106吸入溶液正在进行临床前研究，计划于2023年Q2进行pre-IND申报。双方同意后续就该项目展开临床研究合作，健康元取得本品中国大陆的生产及销售权，金瑞参与销售分成。双方同意针对J RF106 项目下的其他新的适应症、新剂型、复方制剂的研究双方团队紧密合作完成。 成都金瑞基业生物科技有限公司是一家聚焦抗肿瘤、自身免疫、呼吸系统疾病药物研发的医药科技企业。公司拥有多名行业资深专家带领的专业研发团队，致力于解决未被满足的迫切临床需求、研发具有临床优势及市场空间的创新药。经过十多年积累和发展，研发并布局具有全球竞争力及市场潜力的在研产品十多个，包括全球首创及 me better药物 ，多个品种已进入临床阶段。 健康元药业集团始创于 1992年，在创新和高壁垒技术平台的双轮驱动下，现已成为一家创新科研型的综合医药集团。集团旗下拥有健康元、丽珠医药两家大型上市公司，20余家主要控股子公司。 集团 始终坚持以科技创新为战略基点，以打造创新药和高壁垒复杂制剂技术平台双轮驱动为战略目标，围绕呼吸、消化道、辅助生殖、精神、肿瘤等具有显著临床需求的领域进行了丰富的管线布局，形成了丰富多元的产品矩阵及在研药物管线 。 目前已布局 4大创新高壁垒复杂制剂研发平台 。 本次签约，双方本着优势互补、互惠互利、平等合作的原则，充分利用金瑞基业生物科技在科学研究方面的优势和健康元产业化、商业化及呼吸疾病领域的优势，共同研发创新药物。 符合 双方 战略发展规划。 转自：每日经济新闻

July 25, 2022 12:00 UTC GENOA, Italy--(BUSINESS WIRE)-- IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, and PsychoGenics Inc. Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service agreement to identify the efficacy of novel drug candidates in drug-resistant epilepsy. Under the terms of the agreement, PsychoGenics will evaluate the preclinical anti-seizure efficacy of first-in-class selective-NKCC1 inhibitors, which aims to reduce intracellular chloride concentration and restore the physiological hyperpolarizing and inhibitory GABAergic transmission in an animal model of refractory epilepsy. "PsychoGenics is a leader in preclinical behavioral neurobiology with a successful track record of anti-epilepsy drug testing through translational EEG approaches, including electrographic and behavioral identification of seizure," said Andrea P. Malizia, Ph.D., MBA, Chief Executive Officer of IAMA Therapeutics. "We look forward to leveraging our collective expertise in neuroscience drug development to identify and evaluate the anti-seizure efficacy of new drug candidates, to enhance further and complement our pipeline of differentiated therapeutic opportunities for epilepsy, neurodevelopmental and cognitive disorders." “We are excited to embark of these studies with IAMA Therapeutics” said Stephen Morairty, Ph.D., Vice President of Translational Neuroscience at PsychoGenics. “Using our pre-clinical MTLE model, will carefully evaluate the efficacy of these first-in-class selective-NKCC1 inhibitors.” About IAMA Therapeutics IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children and adults suffering from epilepsy, neurodevelopmental and cognitive disorders. IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline to selectively inhibit the sodium-potassium chloride cotransporter and other therapeutic targets relevant to brain disorders characterized by neuronal imbalance. The company's preclinical pipeline consists of the lead candidate IAMA-6 for the treatment of idiopathic autism, IAMA-097 for the treatment of secondary and rare forms of autism, and other compounds for treating refractory epilepsy and other brain disorders. For more information, please visit About PsychoGenics Inc. PsychoGenics is a leader in vivo phenotypic drug discovery. The company applies its proprietary technology platforms in partnership with pharmaceutical and biotechnology companies to discover the next generation of drugs for neuropsychiatric disorders. PsychoGenics' capabilities include standard behavioral testing, electrophysiology, translational EEG, molecular biology, and state-of-the-art microdialysis. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington's disease, Autism spectrum disorders, psychosis/schizophrenia, Alzheimer's disease, Parkinson's disease, sleep, and Spinal Muscular Atrophy (SMA), muscular dystrophy and other muscle disorders. For more information on PsychoGenics Inc., visit .

GENOA, Italy--(BUSINESS WIRE)-- IAMA Therapeutics, a preclinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel medicines to make a difference in the lives of individuals suffering from brain disorders, announced today it will present a poster at the upcoming International Neuroscience Conference of the Federation of the European Neuroscience Societies (FENS). The conference will take place in Paris, France, from July 9-13, 2022. “We are excited to release preclinical data for selective NKCC1-inhibitors from our neuroscience drug discovery initiative, which we believe has the potential to fundamentally redefine the therapeutic opportunities for children and adults with neurodevelopmental and cognitive disorders. These results demonstrated that our candidates led to meaningful and durable responses in animal models of Down syndrome and autism spectrum disorders with no apparent observed toxicity,” said Andrea P. Malizia, PhD, MBA, Chief Executive Officer of IAMA Therapeutics. Details of the poster presentation are as follows: Title: Selective NKCC1 inhibitors for the treatment of Autism, Down syndrome, and brain disorders with defective neuronal Cl homeostasis. Presenter: Annalisa Savardi PhD, Team Leader in Neuropharmacology, IAMA Therapeutics. Poster Session: 03 Board Number: S03-386 Session Date and Time: Monday, July 11, 2022, 09:30 AM-1:00 PM (CET) About IAMA-6 IAMA-6 is a first-in-class selective-NKCC1 inhibitor that modulates the intracellular chloride, reducing the depolarizing strength of GABAA receptors to the levels required to restore the inhibitory transmission. This pathway is reported in Down syndrome, autism spectrum disorder, epilepsy, and other brain disorders characterized by increased intracellular chloride and depolarizing GABAergic transmission. About IAMA Therapeutics IAMA Therapeutics is a preclinical-stage pharmaceutical company focused on discovering, developing, and commercializing novel medicines to make a difference in the lives of children and adults suffering from neurodevelopmental and cognitive disorders. IAMA Therapeutics couples emerging advances in drug discovery and neurobiology to build a leading, next-generation neuroscience pipeline to selectively inhibit the sodium-potassium chloride cotransporter and other therapeutic targets relevant to brain disorders characterized by neuronal imbalance. The company’s preclinical pipeline consists of the lead candidate IAMA-6 for the treatment of idiopathic autism, IAMA-097 for the treatment of secondary and rare forms of autism, and other compounds for the treatment of refractory epilepsy and other brain disorders.